Dr. Stein on Commercial Tests to Determine Therapies for Prostate Cancer

Mark Stein, MD
Published: Wednesday, Jan 18, 2017



Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses commercial tests for determining therapies for patients with prostate cancer.

Certain tests are helpful when understanding some of the more challenging clinical situations, explains Stein. It is not something that is routinely done, due to different insurance funds. However, it is effective during certain cases, in regards to determining which therapy a patient should receive.

Technology and platforms are developing quickly, making it necessary for physicians to remain updated on the ongoing trials in order to decide the most beneficial treatment for a patient. For instance, explains Stein, there might be trials looking at a particular biomarker, which could be an important way to determine which trials to enroll patients on.
 
SELECTED
LANGUAGE


Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses commercial tests for determining therapies for patients with prostate cancer.

Certain tests are helpful when understanding some of the more challenging clinical situations, explains Stein. It is not something that is routinely done, due to different insurance funds. However, it is effective during certain cases, in regards to determining which therapy a patient should receive.

Technology and platforms are developing quickly, making it necessary for physicians to remain updated on the ongoing trials in order to decide the most beneficial treatment for a patient. For instance, explains Stein, there might be trials looking at a particular biomarker, which could be an important way to determine which trials to enroll patients on.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x